Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
4.26
Nov 20 • 3:59 PM ET Dollar change-0.95 Percentage change(-18.23%)
Aftermarket Close
4.26
Aftermarket • 5:55 PM ET Dollar change0.00 Percentage change(0.00%)
Today, 8:35 AMSavara said the FDA will miss the Nov. 22 PDUFA target date for molgramostim’s autoimmune PAP application, with no revised action date provided.
Index
RUT
Market Cap
939.86M
Enterprise Value
840.57M
Income
-152.74M
Sales
0.00M
Book/sh
0.52
Cash/sh
0.59
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
70
IPO
Oct 16, 2000
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
8.12
P/C
7.25
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
8.55
Current Ratio
8.55
Debt/Eq
0.28
LT Debt/Eq
0.28
Option/Short
Yes / Yes
EPS (ttm)
-0.61
EPS next Y
-0.41
EPS next Q
-0.17
EPS this Y
-19.80%
EPS next Y
35.81%
EPS next 5Y
-
EPS past 3/5Y
-28.87% 8.57%
Sales past 3/5Y
- -
EPS Y/Y TTM
-13.83%
Sales Y/Y TTM
-
EPS Q/Q
-23.79%
Sales Q/Q
-
Insider Own
49.88%
Insider Trans
-0.36%
Inst Own
67.37%
Inst Trans
1.10%
ROA
-102.90%
ROE
-151.05%
ROIC
-110.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-10.29%
SMA50
-12.32%
SMA200
-19.84%
Trades
Shs Outstand
205.54M
Shs Float
110.58M
52W High
7.01 -39.19%
52W Low
4.13 3.15%
Volatility
7.82% 7.31%
ATR (14)
0.39
RSI (14)
41.95
Beta
0.27
Rel Volume
6.63
Avg Volume
2.57M
Volume
17,013,117
Perf Week
-8.19%
Perf Month
-6.17%
Perf Quarter
-23.38%
Perf Half Y
-15.14%
Perf YTD
-29.35%
Perf Year
-8.78%
Perf 3Y
13.60%
Perf 5Y
294.44%
Perf 10Y
-17.20%
Prev Close
5.21
Price
4.26
Change %
-18.23%
Consensus
Strong Buy
Avg. Price Target
$10.83
Implied Upside
+154.2%
Analysts11incl. previous ratings
Rating Distribution8 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 12, 2026Resumed
HH.C. Wainwright
Buy$10+134.7%
Oct 07, 2026Initiated
JPM logoJJP Morgan
Overweight$12+181.7%
Apr 24, 2026Resumed
OPY logoOOppenheimer
Outperform$9 → $11+158.2%
Oct 20, 2025Initiated
WFC logoWWells Fargo
Overweight$7+64.3%
Aug 15, 2025Upgrade
HH.C. Wainwright
Neutral → Buy$5+17.4%
May 29, 2025Downgrade
HH.C. Wainwright
Buy → Neutral$2-53.1%
Dec 20, 2024Initiated
WFC logoWWells Fargo
Overweight$8+87.8%
Nov 13, 2024Downgrade
EVR logoEEvercore ISI
Outperform → In-line$7 → $5+17.4%
Feb 15, 2024Initiated
JJMP Securities
Mkt Outperform$8+87.8%
Nov 07, 2023Initiated
GGuggenheim
Buy$7+64.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lowrance David LChief Financial OfficerJun 22 '26Option Exercise1.76580,1871,021,116983,947Jun 22 08:18 PM
Lowrance David LChief Financial OfficerJun 22 '26Sale5.68394,5282,241,432536,032Jun 22 08:18 PM
Lowrance David LOfficerJun 22 '26Proposed Sale5.65394,5282,229,000Jun 22 03:09 PM
Lowrance David LChief Financial OfficerMar 18 '26Option Exercise1.60366,747588,455552,550Mar 20 04:16 PM
McCracken Joseph SDirectorFeb 16 '26Option Exercise1.761,8073,180302,644Feb 17 05:30 PM
RAMSAY DAVID ADirectorDec 19 '25Sale6.0620,000121,2202,533,642Dec 19 05:00 PM
RAMSAY DAVID ADirectorDec 18 '25Proposed Sale6.1120,000122,200Dec 18 11:17 AM
Elam Nevan CDirectorDec 02 '25Option Exercise1.465,8608,55668,360Dec 04 06:55 PM
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Yardley, PA.
M.B.A.Mr. Matthew Pauls J.D.
COO & CFOMr. Robert Matthew Lutz M.B.A.
Ph.D.Dr. Yasmine Wasfi M.D.
Chief Legal OfficerMs. Kate McCabe J.D.
Chief People OfficerMs. Megan Carpenter